Veracyte, Inc.

NasdaqGM:VCYT

Sector

🏥 Health Care

Industries

🔬 Clinical Trials

📊 Big Data

🧬 Biotechnology

🩺 Medical Instruments

💻 Telehealth

Location

United States

Market Cap

USD 2.10 B

Share Price

USD 26.82

Avg Daily Volume

1,025,626

Change (1 day)

0.22%

Change (1 year)

25.27%

Change (YTD)

-32.27%

Veracyte, Inc. Quick Ratio for the Trailing 12 Months (TTM) ending March 31, 2025: 4.55

Veracyte, Inc. Quick Ratio is 4.55 for the Trailing 12 Months (TTM) ending March 31, 2025, a 2.15% change year over year. Quick ratio measures the short-term obligations coverage with liquid assets; higher ratio indicates strong liquidity position.

Veracyte, Inc. Quick Ratio for the Trailing 12 Months (TTM) ending March 31, 2024 was 4.45, a 14.62% change year over year.
Veracyte, Inc. Quick Ratio for the Trailing 12 Months (TTM) ending March 31, 2023 was 3.88, a -20.69% change year over year.
Veracyte, Inc. Quick Ratio for the Trailing 12 Months (TTM) ending March 31, 2022 was 4.90, a -70.23% change year over year.
Veracyte, Inc. Quick Ratio for the Trailing 12 Months (TTM) ending March 31, 2021 was 16.45, a 42.68% change year over year.

Quarterly
Annual
TTM

From:

To:

Zoom:

Key data

Date	Quick Ratio	Current Ratio	Interest Coverage Ratio	Return on Capital Employed (ROCE)

NasdaqGM: VCYT

Veracyte, Inc.

CEO	Mr. Marc A. Stapley
IPO Date	Oct. 30, 2013
Location	United States
Headquarters	6000 Shoreline Court
Employees	824
Sector	🏥 Health Care
Industries Clinical Trials 📊 Big Data 🧬 Biotechnology 🩺 Medical Instruments 💻 Telehealth

Description

Veracyte, Inc. operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to determine patients with indeterminate results are benign to avoid unnecessary surgery; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Genomic Sequencing Classifier and Percepta Nasal Swab Test for lung cancer diagnosis; Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis; and Immunoscore Colon Cancer test for colon cancer diagnosis. It is also developing Percepta Genomic Atlas to help inform lung cancer treatment decisions; Envisia Classifier, the nCounter analysis system; and LymphMark for lymphoma subtyping test. Veracyte, Inc. has technology licensing and collaboration arrangements with Johnson & Johnson; Acerta Pharma; and CareDx. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.